Recent News

Ketamine infusions elicit different responses among 3 distinct subgroups of individuals dealing with depression and suicidal ideation. One group, remitters, had no suicidal ideation by day 2, and another group, responders, showed improvement independent of depressed mood, according to a study published in the Journal of Affective Disorders.

Researchers pooled data from 5 clinical trials involving treatment-resistant individuals with major depressive disorder or bipolar depression (N=128). All participants received a ketamine infusion and were evaluated at baseline and days 1 through 3. Evaluations included plasma markers to monitor neurotrophic factors, kynurenine pathway analytes, inflammatory cytokines, cortisol, and suicidal ideation composite scores to monitor depressed mood, hopelessness, sadness, and suicidal thoughts.

Read more

Ketamine, a widely used anesthetic that’s also an illicit party drug, has taken on a new role in recent years: treating severe depression in people who have not responded to standard treatment. Researchers have called it the most exciting breakthrough in the field of depression research in the past half-century.

One form of the drug, being developed as a nasal spray called esketamine, is in the final stages of testing needed before it can go to the FDA for approval.

Read more

A low dose of ketamine infusion can provide a rapid and sustained antidepressant effect in patients with treatment-resistant depression, according to a study published in the Journal of Affective Disorders. In addition, a subanesthetic dose of ketamine was shown to improve functional impairment traditionally associated with treatment-resistant depression.

Read more

Average scores on the Children's Depression Rating Scale dropped by 42.5% following low-dose IV ketamine infusions among 13 teenagers with treatment-resistant depression, findings published in Journal of Child and Adolescent Psychopharmacology showed.

“Adult [treatment-resistant depression] research has begun to explore repeated administrations of ketamine, which may have promise for greater effectiveness and longer remission periods than single doses,” Kathryn R. Cullen, MD, division of child and adolescent psychiatry, University of Minnesota Medical School, and colleagues wrote.

Read more

Adolescents treated with intravenous ketamine for treatment-resistant depression showed a significant average decrease— 42.5%—in Children’s Depression Rating Scale scores, according to a small, open-label study published online in the Journal of Child and Adolescent Psychopharmacology.

“Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed,” wrote researchers. “Ketamine has been studied in adults with TRD, but little information is available for adolescents.”

Read more

In patients with severe depression and thoughts of suicide, ketamine is emerging as a potential treatment. Patients are given roughly 5 to 6 injections of the party drug and have reported almost immediate relief from suicidal thoughts and major depressive disorder.

One such patient, Alan Ferguson, had been battling depression his whole life and had attempted suicide multiple times. In the midst of a major depressive episode, the 54-year-old was put in touch with Dr. Kevin Lane, an anesthesiologist who is currently administering ketamine treatments. After receiving one treatment of intravenous ketamine therapy, Ferguson claims to have woken up the next day with no thoughts of suicide. Receiving three of the injections in total, he describes the drug as a “medical marvel”.

Read more

A few months ago, Alan Ferguson decided he was ready to die -- for the third time. In 2014, he attempted suicide twice, and the persistent thoughts of "I need to be dead" were echoing in his brain once again.

Now 54 years old, Ferguson was diagnosed with clinical depression when he was 18. Since then, he estimates, he's been prescribed more than a dozen medications -- SSRIs, SNRIs, tricyclic antidepressants -- all to little or no avail.

Read more

A new study has shown a significant average decrease in the Children's Depression Rating Scale (42.5%) among adolescents with treatment-resistant depression (TRD) who were treated with intravenous ketamine. The study, which demonstrated the tolerability and potential role of ketamine as a treatment option for adolescents with TRD, is published in Journal of Child and Adolescent Psychopharmacology.

Read more

There’s a new treatment that’s gaining traction as a wonder drug for depression — and that’s ketamine. According to its advocates, medically administered ketamine infusions have the potential to revolutionize the way doctors treat depression — and give people struggling with depression unprecedented relief from their symptoms.

For people struggling with depression, treatment is crucial. Unfortunately, traditional treatments don’t work for everyone; about 30% of people with depression don’t respond to traditional pharmaceutical treatment, and even for people who do respond, antidepressants can take up to eight weeks to take effect — which, when you’re struggling with depression, can feel like a lifetime.

Read more

A North Texas woman said a popular club drug and animal tranquilizer saved her from a life of depression and suicidal thoughts.

You may have heard of the drug before, as Special K on the street. it was designed as a horse tranquilizer, but Ketamine is gaining popularity as a treatment for depression.

Some doctors believe the controversial drug will become a game-changer in slowing the nation's suicide epidemic.

Read more

I am here because I cannot stop thinking about suicide. I’ve been in therapy on and off for more than 30 years, since I was 5, and on depression medication for more than a decade. Nothing seemed to work. I couldn’t stop imagining killing myself in increasingly vivid daydreams.

As a journalist who covers health and medicine, I had read about the success of experimental trials that used ketamine to treat depression. My therapists had recommended extreme treatments like electroshock therapy, a procedure that frightened me due to reports of memory loss from those who had undergone it, but had never mentioned this. But I was getting desperate for a serious intervention.

Read more

Ketamine was developed as an anesthetic for surgery and trauma. It was approved by the FDA in 1970 for human use, with indications as for the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. Ketamine was then literally battle-tested during the Vietnam War, where it was vital in caring for wounded soldiers.

Read more

While depression is a treatable condition, some individuals do not respond to conventional prescription medications or talk therapies.

It can be a long and frustrating road for those with treatment-resistant depression who seek help, but Dr. Pierre Blier, Director of Mood Disorder Research at The Royal’s Institute of Mental Health Research (IMHR), has been able to offer hope to some of these individuals, via a cutting-edge treatment that uses an old drug in a new and effective way.

Read more

RENO, Nev. — Dr. Robert Watson was walking to the hospital one day when he heard a woman call out to him.

The woman, he quickly realized, was the mother of a patient whom he recently treated. "She told me, 'Oh my gosh! Thank you; thank you so much!'" Watson recalled.

Not long before, the woman had called Dr. Watson's office out of desperation. She was seeking help for her daughter, who was suffering from an anxiety disorder — she was crippled by it and unable to work.​

Read more

Ketamine has caused quite a stir in psychiatric practice. Sub-anesthetic administrations of ketamine have been shown to markedly improve symptoms of depression and anxiety. While the growing off-label use of ketamine speaks to the need for novel approaches to psychiatric care and treatment-resistant illness, it also presents an ethical dilemma, wherein widespread adoption has once again leaped ahead of scientific understanding.

Read more

For six years now, life has been really good for James. He has a great job as the creative director of an advertising firm in New York City. He enjoys spending time with his wife and kids.

And it has all been possible, he says, because for the past six years he has been taking a drug called ketamine.

Before ketamine, James was unable to work or focus his thoughts. His mind was filled with violent images. And his mood could go from ebullient to dark in a matter of minutes.

Ketamine "helped me get my life back," says James.

Read more

Every week, when Ian Hanley sits down with his therapist, he goes through a list of depression treatments he’s been researching online. The best-known treatments at the top of the list–half a dozen antidepressants and known combinations of those drugs–are all crossed out.

“My therapist says he’s never had this much difficulty with somebody,” says Hanley, “which is sort of a dubious honor.”

Hanley is only 21 years old, but he’s already six years into his search for something, anything, that can help him feel better for more than a few weeks at a time.

Read more

Results of a recent study indicate that response to ketamine treatment in mood disorders may be better predicted based on existing baseline metabolic-inflammatory alterations, most notably cognitive impairment.

Researchers aimed to identify mood disorder subpopulations that were more, or less, likely to respond to treatment with ketamine. Current literature indicates that ketamine has a quick antidepressant effect on treatment-resistant depression symptoms in patients with both major depressive disorder (MDD) and bipolar disorder. The authors focused their study on predictive pretreatment elements in these disorders.

They searched PubMed/MEDLINE, ClinicalTrials.gov, and Scopus for relevant literature and bibliographies that included terms such as major depressive disorder, depression, bipolar disorder, remission.

Read more

Like a May shower, the studies on psychedelic drugs' potential therapeutic benefits came — first as a sprinkle, then a steady downpour. Between 2012 and 2017, the papers abounded. One, published in 2016, suggested that magic mushrooms might alleviate anxiety in cancer patients; another in 2017 indicated that ecstasy could help veteranscope with PTSD symptoms; and one in 2012 hinted that ketamine might curb major depression.

Recently, the shower has turned into a trickle. But that spate of published research on psychedelics now seems to be leading to the development some promising potential treatments.

Read more

It all started with ketamine. To some, vets mainly, it’s a horse tranquilizer. To others, a party drug. To those with severe clinical depression, a potential, literal, life-saver. A dose of ketamine can rapidly dull the symptoms of depression, providing immediate relief for those crippled by the darkest thoughts. And while ketamine does not work for everyone, it seems to work in many people who are untouched by standard antidepressant drugs.

Ketamine could then be our best lead in the hunt for depression. For if we search for where ketamine affects the brain, and for how it affects the brain, we will get vital clues to the cause of depression. And so to a long-lasting effective treatment. Two studies just published in Nature used precisely this trick, and spectacularly uncovered not just compelling evidence of the tiny brain region to target, but exactly what goes wrong in it to create depression — that some neurons are, literally, depressed.

Read more

When confronted with a suicidal patient, doctors could turn to a substance with uses that range from psychedelic party drug to animal anesthetic.

It’s called ketamine, a class III scheduled drug known for its similarities to PCP and its ability to induce dissociative and hallucinogenic feelings. The drug is the most commonly used among veterinarians for anesthetic purposes, according to Medical News Today, but is often illegally used in clubs and as a date-rape drug.

And now a study published in The American Journal of Psychiatry suggests the powerful drug could also help treat suicidal people.

Read more

Don’t people take ketamine at raves?
Well, yeah. Club kids call it Special K and snort it for its dissociative, dreamy effects. But it’s also been used as a (legal) anesthetic since the ’70s. In the early 2000s, doctors realized it quickly treats depression and began prescribing it in small doses. Researchers theorize it works by blocking cells from firing in the lateral habenula, an area of the brain that represses reward centers, according to a study released in February. (Maybe it’s also got something to do with those dissociative effects?)

How does it get administered at clinics?

First, you need a prescription from your doctor. Then, after a consultation at the clinic, you’ll hang out in a recliner for 45 minutes or so while an IV drip infuses the drug into your bloodstream. A nurse monitors your blood pressure and heart rate. (Be wary if the clinic doesn’t track your vitals.)

Read more

It's been called "the most important discovery in half a century," and for some of the people who have tried ketamine, it may feel that way too.

The compound has a reputation as a party drug, but ketamine is increasingly being studied for its potential use as a rapid-fire treatment for depression. In people who live with the disease, thoughts of suicide can strike suddenly and without warning. Fast-acting, successful interventions are hard to come by.

But a spate of recent research suggests that ketamine could provide quick and powerful relief — even to people whose depression has repeatedly failed to respond to other medications and to those who are suicidal.

Read more

The notorious party drug may act as an antidepressant by blocking neural bursts in a little-understood brain region that may drive depression​.​​

Ketamine has been called the biggest thing to happen to psychiatry in 50 years, due to its uniquely rapid and sustained antidepressant effects. It improves symptoms in as little as 30 minutes, compared with weeks or even months for existing antidepressants, and is effective even for the roughly one third of patients with so-called treatment-resistant depression.

Read more

Unipolar major depressive disorder (MDD) is one of the leading causes of disability, affecting 16 million individuals in the United States, and more than 300 million individuals worldwide experience depression. Roughly one-third of patients with MDD do not respond to currently approved antidepressants, and even in those who do, these agents typically take several weeks or even months to achieve a significant effect.

“There is a major unmet need for more effective and rapidly acting antidepressants,” commented Dan V. Iosifescu, MD, director of clinical research, at the Nathan Kline Institute and associate professor of psychiatry at New York University School of Medicine.

Read more

What is transcranial magnetic stimulation, and how does it work? Is it effective for treating depression?

Transcranial magnetic stimulation, or TMS, is a procedure that uses magnetic fields to stimulate nerve cells in the brain. It’s a noninvasive procedure that usually requires about 25 to 30 treatment sessions. Transcranial magnetic stimulation has been shown to effectively improve symptoms of depression, particularly in people who haven’t seen improvement with other treatments, such as antidepressant medications and psychotherapy.

Read more

The US Food and Drug Administration (FDA) has approved a new magnetic stimulation device that is designed to treat patients with treatment-resistant major depressive disorder (MDD) in just 3 minutes.

The Express Transcranial Magnetic Stimulation (TMS) device, from MagVenture, has been approved by the FDA—expediting the treatment session speed set only by the company’s preceding TMS device when it was first cleared in 2008. What was once a treatment regimen that required patients with MDD to undergo a 30-minute-plus session 20-30 times, is now capable of being completed in just 3 minutes per session.

Read more

Open-label transcranial magnetic stimulation (TMS) reduced suicidal ideation in adolescents with treatment-resistant depression, according to the results of a study published in the Journal of Affective Disorders.

Suicide is a leading cause of death among adolescents worldwide.

In the United States, nearly 20% of adolescents [KL1] consider suicide, 15% have formulated plans for suicide, and almost 10% attempt suicide annually. Despite efforts to reduce suicide, the rate of suicide attempts and successful suicide continues to increase in the United States. Early attempts also predict similar behavior in adulthood.

Read more

ORANGE, Calif. - For about 30 percent of adults with major depression, simply taking medications isn't effective enough. This group has what doctors call "treatment-resistant" depression and finding relief can often be frustrating.

But there are new alternatives that don't involve medication at all, neuro-stimulators that prod certain parts of the brain to work.

Carolyn Radillo has been fighting treatment-resistant depression since she was a teenager. She's tried therapy, many medications and has been hospitalized four times without much relief.

Her doctor told her about a new treatment and she was open to trying it.

Read more

If you follow neuroscience and neuroengineering, it’s hard to ignore the offerings of cutting-edge research seeming to reanimate an antediluvian procedure of pelting the brain with electricity. Today’s more modern and civilized brain zapping is less invasive, more controlled and uses various levels of direct and alternating electrical currents to repair and augment a panoply of different cognitive functions. Results range from relieving severe, treatment-resistant depression, jumpstarting vocabulary recall, enhancing math skills, boosting self-control, fortifying the aging brain as well as reducing the intention to commit violent acts and sexual assault.

Read more

The effect of an acute course of high-frequency repetitive Transcranial magnetic stimulation (TMS) on suicidal ideation in adolescents was examined in this exploratory study. Researchers obtained data from 3 prior protocols providing a 30-session course of open-label TMS treatment for adolescents with treatment-resistant depression . . . Findings revealed that in adolescents, open-label TMS alleviated suicidal ideation through the treatment and improvement of depressive symptom severity.

Read more

The National Institutes of Health reports that about 30 percent of adults with major depression don’t respond to treatment.

But those people have an alternative that doesn’t involve medication and is non-invasive. There are a new generation of neurostimulators, which prod certain parts of the brain to work.

Carolyn Radillo has been fighting treatment-resistant depression since she was a teenager. She’s had lots of therapy, many medications and has been hospitalized four times without much relief.
​
Read more

JACKSONVILLE, Fla. - Major depression is one of the most common medical disorders in the United States. Unfortunately, many people go untreated or have trouble finding medications that work. But there's a newer treatment that's literally tapping into a patient's brain to ease the depression without serious side effects.

This treatment, known as transcranial magnetic stimulation, or TMS, changed a Florida mom's life. We'll call her "Gina" because she doesn't want to reveal her identity due to the stigma associated with depression. However, she does want everyone to know her story in hopes of helping save someone else.

Read more

Sessions of magnetic brain stimulation therapy lasting just over three minutes significantly reduce depression symptoms in patients with treatment-resistant depression. That’s according to the largest study of its kind comparing a standard form of brain stimulation with a newer, shorter version that could potentially treat a larger percentage of depression patients.

Read more

It’s every psychiatrist’s dilemma: Two patients sit in front of you, displaying the same symptoms and the same diagnosis. After going through the same treatment, one recovers and one doesn’t. What’s the difference?

It very well could be inside the brain itself. Scientists have learned a lot about the brain in the last few decades, but mental illnesses are still diagnosed based on symptoms—the visible tips of a tower hidden in fog. But for each person a different part of the tower may be broken.

Read more

According to the latest estimates, more than 300 million people worldwide are living with depression. Medication and talk therapy are effective treatments for most patients— but not all.

If first-line treatments don't work, some people with depression turn to brain stimulation therapies. One such treatment is transcranial magnetic stimulation (TMS), which uses a pulsed magnetic field to stimulate nerve cells — or neurons — in the regions of the brain that regulate mood. When stimulated, the neurons release neurotransmitters like serotonin, which are otherwise depleted in people with depression.

Read more

A specific kind of brain stimulation may be effective in reducing suicidal thinking in people with hard-to-treat depression, as well as other mental illnesses, according to a study. Forty per cent of people in the study, published in The Journal of Clinical Psychiatry, reported that they no longer experienced suicidal thoughts after receiving bilateral repetitive transcranial magnetic stimulation (rTMS).

"This is one of the first large studies showing rTMS is effective in treating suicidal ideation," said Jeff Daskalakis from Centre for Addiction and Mental Health (CAMH) in Canada. "The effects on suicidal ideation were independent of effects on depressive symptom."

Read more

Repetitive transcranial magnetic stimulation (rTMS) may help improve refractory depression in patients with borderline personality disorder, according to research presented at the American Psychiatric Association’s annual meeting.

“Borderline personality disorder patients have a high lifetime prevalence of major depressive disorder,” wrote poster presenter Hyewon Helen Lee, MD, in an abstract presented May 7. “However, it has been previously found that there are poorer outcomes of electroconvulsive therapy and antidepressants among this population.”​

Read more

Repetitive transcranial magnetic stimulation (rTMS) may help improve refractory depression in patients with borderline personality disorder, according to research presented at the American Psychiatric Association’s annual meeting.

A specific type of non-invasive brain stimulation, known as rTMS (repetitive transcranial magnetic stimulation), can reduce suicidal thinking in a significant portion of people with hard-to-treat depression, according to a new study published in The Journal of Clinical Psychiatry.

In fact, 40 percent of the study participants who underwent bilateral rTMS reported that they were no longer experiencing suicidal thoughts. The brain stimulation works by directing magnetic pulses at targeted areas of the brain.

Read more

Intermittent theta burst stimulation, a shorter version of the 37-minute repetitive transcranial magnetic stimulation that can be delivered in 3 minutes, was noninferior to the longer version for treatment-resistant depression, findings published in The Lancet revealed.

“Several pilot trials and two meta-analyses indicate that [intermittent theta burst stimulation] is superior to sham treatment for treatment-resistant depression. However, the key practical question is whether [intermittent theta burst stimulation] performs comparably to the existing standard of care,” Daniel M. Blumberger, MD,of the department of psychiatry, University of Toronto, and colleagues wrote.

Read more

A study published in the Journal of Affective Disorders demonstrated the cognitive safety of H1-coil transcranial magnetic stimulation (TMS) treatment for individuals with bipolar depression.

The exploratory study sought to evaluate the effects of H1-coil TMS treatment on 6 cognitive domains (attention and processing speed, inhibitory control, working memory and executive function, language, immediate verbal memory, and long-term verbal memory) in subjects with bipolar depression.

Read more

TORONTO, April 26, 2018 – In the largest study of its kind, a three-minute version of a brain stimulation treatment was shown to be just as effective as the standard 37-minute version for hard-to-treat depression.

These results were published in a new Canadian study in The Lancet co-led by the Centre for Addiction and Mental Health (CAMH) and the University Health Network's Krembil Research Institute, in collaboration with the University of British Columbia.

The treatment is called repetitive transcranial magnetic stimulation (rTMS), which is a form of treatment that uses magnetic field pulses to non-invasively stimulate a part of the brain called the dorsolateral prefrontal cortex, which is associated with mood regulation. The study compared standard rTMS treatment, which uses high frequency (10 Hz) brain stimulation for 37.5 minutes per session, with a newer form of rTMS called intermittent theta burst stimulation (iTBS), that mimics the brain's natural rhythms and takes just over three minutes per treatment.

Read more

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive treatment approved by the U.S. Food and Drug Administration for the treatment of clinical depression. The treatment is also being studied as a potential therapy for Alzheimer’s disease.

How rTMS works:
Alzheimer’s disease is the most common cause of dementia, affecting millions of mostly elderly people around the world. In these people, the synaptic activity (connections between nerve cells) collapses and brain networks gradually falter, resulting in a decline in memory and the ability to think and learn.

Read more

Some pill-averse patients have longed for a natural cure for depression, while others complain that the drugs they’re on aren’t enough. Hope for both groups may have arrived through an unlikely source: magnets.

Read more

For most of my 46 years, I have battled mild to severe depression and anxiety. Mood disorders run like a sticky red tape through my family, so it wasn’t a surprise that I needed a psychiatrist’s care starting as a young child. He helped me push on through middle and high school.

But when I went to college – away from my support system – I started thinking about suicide. Hearing this, a campus psychiatrist had me hospitalized, which only increased my despair. I attempted suicide and was institutionalized even longer.

Read more

Repetitive Transcranial Magnetic Stimulation (rTMS), a therapy in which electromagnetic fields are pulsed through a coil placed on the scalp, can produce antidepressant effects in individuals who are resistant to or unable to tolerate standard antidepressant drugs. Now, a new study published in the journal BrainStimulation suggests that a new means of delivering rTMS, a “two-coil array,” can be safely used and may help to stimulate deeper areas of the brain than the current single-coil designs.

Read more